Amphastar Pharmaceuticals vs Emergent Biosolutions
Amphastar Pharmaceuticals and Emergent Biosolutions are similar in size: $720m and $743m of revenue in their latest fiscal years. Amphastar Pharmaceuticals grew faster (-1.7% against -28.8%). Amphastar Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 13.6% against 7.1%. Amphastar Pharmaceuticals carries less debt relative to equity (78.8% against 112.8%).
| Latest fiscal year | Amphastar PharmaceuticalsAMPH, 2025 | Emergent BiosolutionsEBS, 2025 |
|---|---|---|
| Revenue | $720m | $743m |
| Revenue growth | -1.7% | -28.8% |
| Net income | $98.1m | $52.6m |
| Operating margin | 19.5% | 13.5% |
| Net margin | 13.6% | 7.1% |
| Return on equity | 12.9% | 10.5% |
| Free cash flow | $121m | $157m |
| Cash | $170m | $205m |
| Total debt | $621m | $590m |
| Debt to equity | 78.8% | 112.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $75.6m | $24.9m |
| Employees | 1,976 | 900 |
| Market value | $1.15bn | $330m |
| Price vs our value range | Below our value range | Below our value range |
| Moat score | 59 (Moderate) | 27 (Weak) |
| Insider trades, 12 months | 0 buys, 11 sales | 0 buys, 15 sales |